An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A

NCT02234323 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

108

Enrollment

INDUSTRY

Sponsor class

Conditions

Hemophilia A

Interventions

BIOLOGICAL: rFVIIIFc

Sponsor

Bioverativ, a Sanofi company

Collaborators

[object Object]